文献速递骨质疏松与钙磷/甲状旁腺

治疗相关骨密度变化作为骨折风险降低的替代生物标志物:多项随机对照试验个体患者数据的荟萃回归分析

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-01-01

该研究汇总了23项随机安慰剂对照试验中91779名骨折风险升高男女的个体数据,通过荟萃回归分析发现,治疗相关的髋部、股骨颈和脊柱骨密度变化与椎体、髋部和非椎体骨折风险降低显著相关,髋部骨密度变化可解释44%至67%的治疗相关骨折风险降低,支持将骨密度作为未来随机试验的替代终点。

要点

  • 治疗相关髋部、股骨颈和脊柱骨密度变化与椎体、髋部及非椎体骨折风险降低显著相关。
  • 髋部骨密度变化可解释44%至67%的治疗相关骨折风险降低。
  • 未来试验中,总髋部骨密度24个月最小百分比变化需达1.42%至3.18%方可几乎确定减少骨折。

核心结论

  • 治疗相关骨密度变化与不同作用机制骨质疏松治疗随机试验中的骨折减少强烈相关,支持骨密度作为未来随机试验的替代终点。

研究设计与样本

  • 对多项随机安慰剂对照临床试验的个体患者数据进行汇总分析,纳入23项多中心、随机、安慰剂对照、双盲骨质疏松药物试验,共91779名骨折风险升高的男女参与者,随访1至9年。

主要发现

  • 荟萃回归显示,治疗相关髋部、股骨颈和脊柱骨密度变化与椎体骨折减少显著相关(r²分别为0.73,p<0.0001;0.59,p=0.0005;0.61,p=0.0003)。
  • 治疗相关髋部、股骨颈和脊柱骨密度变化与髋部骨折减少显著相关(r²分别为0.41,p=0.014;0.41,p=0.0074;0.34,p=0.023)。
  • 治疗相关髋部、股骨颈和脊柱骨密度变化与非椎体骨折减少显著相关(r²分别为0.53,p=0.0021;0.65,p<0.0001;0.51,p=0.0019)。
  • 未来试验中,总髋部骨密度24个月最小百分比变化提供几乎确定骨折减少的范围为1.42%至3.18%,取决于骨折部位。
  • 髋部骨密度变化解释了治疗相关骨折风险降低的较大比例(44%至67%)。

关键数值与推荐

  • 未来试验中,总髋部骨密度24个月最小百分比变化需达1.42%至3.18%方可几乎确定减少骨折,具体取决于骨折部位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The validation of bone mineral density (BMD) as a surrogate outcome for fracture would allow the size of future randomised controlled osteoporosis registration trials to be reduced. We aimed to determine the association between treatment-related changes in BMD, assessed by dual-energy x-ray absorptiometry, and fracture outcomes, including the proportion of treatment effect explained by BMD changes. METHODS: We did a pooled analysis of individual patient data from multiple randomised placebo-controlled clinical trials. We included data from multicentre, randomised, placebo-controlled, double-blind trials of osteoporosis medications that included women and men at increased osteoporotic fracture risk. Using individual patient data for each trial we calculated mean 24-month BMD percent change together with fracture reductions and did a meta-regression of the association between treatment-related differences in BMD changes (percentage difference, active minus placebo) and fracture risk reduction. We also used individual patient data to determine the proportion of anti-fracture treatment effect explained by BMD changes and the BMD change needed in future trials to ensure fracture reduction efficacy. FINDINGS: Individual patient data from 91 779 participants of 23 randomised, placebo-controlled trials were included. The trials had 1-9 years of follow-up and included 12 trials of bisphosphonate, one of odanacatib, two of hormone therapy (one of conjugated equine oestrogen and one of conjugated equine oestrogen plus medroxyprogesterone acetate), three of PTH receptor agonists, one of denosumab, and four of selective oestrogen receptor modulator trials. The meta-regression revealed significant associations between treatment-related changes in hip, femoral neck, and spine BMD and reductions in vertebral (r2 0·73, p<0·0001; 0·59, p=0·0005; 0·61, p=0·0003), hip (0·41, p=0·014; 0·41, p=0·0074; 0·34, p=0·023) and non-vertebral fractures (0·53, p=0·0021; 0·65, p<0·0001; 0·51, p=0·0019). Minimum 24-month percentage changes in total hip BMD providing almost certain fracture reductions in future trials ranged from 1·42% to 3·18%, depending on fracture site. Hip BMD changes explained substantial proportions (44-67%) of treatment-related fracture risk reduction. INTERPRETATION: Treatment-related BMD changes are strongly associated with fracture reductions across randomised trials of osteoporosis therapies with differing mechanisms of action. These analyses support BMD as a surrogate outcome for fracture outcomes in future randomised trials of new osteoporosis therapies and provide an important demonstration of the value of public access to individual patient data from multiple trials. FUNDING: Foundation for National Institutes of Health.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020. PMID: 32707115. doi:10.1016/S2213-8587(20)30159-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。